Wilmington Savings Fund Society FSB purchased a new position in iShares Biotechnology ETF (NASDAQ:IBB – Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,809 shares of the financial services provider’s stock, valued at approximately $263,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Darwin Wealth Management LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $29,000. Highline Wealth Partners LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $30,000. Ashton Thomas Securities LLC bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $36,000. Voisard Asset Management Group Inc. bought a new position in shares of iShares Biotechnology ETF in the third quarter valued at approximately $59,000. Finally, Aptus Capital Advisors LLC lifted its holdings in shares of iShares Biotechnology ETF by 36.5% in the third quarter. Aptus Capital Advisors LLC now owns 426 shares of the financial services provider’s stock valued at $62,000 after purchasing an additional 114 shares in the last quarter. Institutional investors own 62.45% of the company’s stock.
iShares Biotechnology ETF Stock Performance
IBB stock opened at $137.66 on Wednesday. The stock’s 50 day moving average is $141.74 and its 200-day moving average is $142.40. iShares Biotechnology ETF has a twelve month low of $123.60 and a twelve month high of $150.57.
iShares Biotechnology ETF Cuts Dividend
About iShares Biotechnology ETF
iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.
See Also
- Five stocks we like better than iShares Biotechnology ETF
- Basic Materials Stocks Investing
- AppLovin Insiders Sell Shares: Stock Price Indicated Higher
- How Can Investors Benefit From After-Hours Trading
- Broadcom’s Stellar Outlook Sparks Hopes for a Semi Sector Rally
- What Are the FAANG Stocks and Are They Good Investments?
- Salesforce’s Clear Path to $400 and Beyond
Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Biotechnology ETF (NASDAQ:IBB – Free Report).
Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.